Categories: Wire Stories

Crest View International Reports On Kodak Shares Soaring Almost 1,500% on Virus Drug Loan Deal

TAIPEI, Taiwan–(BUSINESS WIRE)–Finance executives at respected Taiwanese wealth management company Crest View International has reported on Kodak shares surging 1,481% following heavy trading as the Trump administration offered the former photography industry leader a financial lifeline to manufacture ingredients for drugs to be used to battle coronavirus.

“Kodak’s valuation leapt from $92 million to $1.5 billion as its shares climbed from $2.10 at Friday’s close to $33.20 yesterday,” reported Michael Kennedy, Head of Corporate Trading at Crest View International. “During the first few hours of trading yesterday morning, the stock was halted more than a dozen times, just a day after it had more than tripled in value,” he added.

The intensity of trading far exceeded anything witnessed since the company returned to the New York Stock Exchange after it emerged from bankruptcy in 2013.

Kodak, which is headquartered in Rochester, New York, and the US International Development Finance Corporation, revealed on Tuesday that the company had secured a $765 million loan to manufacture drug ingredients under the Defence Production Act.

According to analysts at Crest View International, Kodak’s shares started to climb on Monday, following an affiliate of CBS, WROC television station, publishing and then deleting a report, saying an announcement from the company was expected on Tuesday. The WROC report did not include specifics on what the two firms would reveal, beyond a COVID-19-related manufacturing agreement.

“By close of trading on Monday, Kodak shares had gained 25% after 1.65 million shares changed hands, which is more than 14 times the daily average of the preceding ten trading days,” reported Robert Woods, Senior Vice President of Crest View International.

On Wednesday, the executive chairman of Kodak, Jim Continenza said that he “couldn’t tell you what influenced that volume” on Monday, however, the team at Kodak “knew for over a week” about the forthcoming announcement. “I mean obviously this has been a pretty tight kept secret, even until the last day,” he said.

Kodak’s trading volumes continued to climb throughout Tuesday and Wednesday, with more than $10.9 billion worth of the stock, around 558 million shares, changing hands.

The Securities and Exchange Commission has refused to say whether it will investigate the surge in trading activity prior to the announcement. Kodak and Nexstar, the owner of WROC, declined to comment.

About Crest View International

Crest View International Limited is a private wealth management company headquartered in Taipei, Taiwan. Crest View International manages over $8.7 billion (USD) on behalf of its clients from around the world.

Related Links

https://www.crestviewcapital.com/

Contacts

Mr. Nathan Hu, Head of Research.

Switchboard +886-2-7741-4004 | Email nathan.hu@crestviewcapital.com
34F, No.68 Sec. 5, Zhongxiao East Road, Xinyi Dist., Taipei City, Taiwan.

Alex

Recent Posts

HKU engineering researchers develop revolutionary diamond fabrication technology

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - A research team…

1 hour ago

Agilis Robotics completes world’s first robot-assisted bladder tumour resection in clinical trial

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - Agilis Robotics has…

2 hours ago

LOFTER GROUP Awarded 12 Honors at PropertyGuru Asia Property Awards, Recognized as Best Boutique Developer (Hong Kong and Macau)

UPPER PRINCE Triumphs as Best Connectivity Condo Development in Asia HONG KONG SAR - Media…

2 hours ago

Delta Dunia Group Delivers Steady 9M 2024 Results with Transformative Milestones to Fuel Long-Term Growth

Despite significant challenges posed by extreme weather conditions in Indonesia and Australia, Delta Dunia Group…

3 hours ago

Exchange Plastic for Rewards with 1win and Recycledge

IBADAN, NIGERIA - Media OutReach Newswire – 20 December 2024 - Leading global iGaming brand…

3 hours ago

AIM Vaccine has obtained clinical approval for two heavyweight products, creating new growth points for performance

HONG KONG SAR - Media OutReach Newswire - 20 December 2024 - AIM Vaccine (06660.HK)…

6 hours ago